UXT Activators
UXT Activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of UXT by modulating various associated signaling pathways, particularly focusing on the NF-kB signaling cascade. Forskolin, for instance, catalyzes the conversion of ATP to cAMP, which subsequently activates PKA. This activation can lead to phosphorylation of components within the NF-kB pathway, thereby potentially enhancing the transcriptional activity of NF-kB, a complex with which UXT is known to interact. Similarly, Curcumin and Sulforaphane modulate the NF-kB pathway by inhibiting IKK and activating Nrf2, respectively, with both actions resulting in an indirect augmentation of NF-kB's transcriptional activity-a process that UXT is postulated to influence. Parthenolide and Cardamonin, by inhibiting NF-kB activation through direct interaction with its subunits or by preventing the phosphorylation of IκBα, increase the nuclear presence of NF-kB, thus enabling UXT to modulate its transcriptional regulation more effectively.
The second group of UXT Activators includes compounds like BAY 11-7082, Resveratrol, and TPCA-1, all of which act upon the IKK complex or NF-kB directly to enhance its activity within the nucleus, presenting opportunities for UXT to enhance NF-kB's transcriptional regulation of genes. PDTC, Anacardic acid, Celastrol, and Withaferin A also exert their effects through the manipulation of the NF-kB pathway, stabilizing IκB or preventing the translocation of NF-kB's p65 subunit, thereby increasing the potential for UXT to modulate NF-kB's activity. These chemical activators, through their targeted effects on the NF-kB signaling pathway, indirectly contribute to the potentiation of UXT's role in transcriptional regulation without directly upregulating its expression or activity. Collectively, these compounds represent a theoretical framework through which the activity of UXT could be enhanced, based on its known interactions with key components of the NF-kB pathway.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels in cells. Elevated cAMP activates PKA, which can phosphorylate various substrates, including those in the NF-kB pathway. This phosphorylation can enhance the transcriptional activity of NF-kB, which UXT is known to modulate indirectly. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Sulforaphane activates Nrf2, leading to antioxidant response element-mediated gene expression. Nrf2 has crosstalk with the NF-kB pathway, potentially enhancing NF-kB activity indirectly. Through this interaction, UXT's modulation of NF-kB activity could be amplified. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits IKK, blocking NF-kB activation. By preventing the phosphorylation and subsequent degradation of IκB, NF-kB remains active in the nucleus longer, where UXT could enhance its transcriptional activity on various genes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is involved in the activation of SIRT1, which can deacetylate and activate NF-kB, leading to enhanced transcriptional activity. As UXT interacts with components of the NF-kB pathway, its functional activity could be enhanced by resveratrol's action on NF-kB. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits NF-kB activation by alkylating the p65 subunit and preventing its nuclear translocation. The sustained cytoplasmic presence of NF-kB could be modulated by UXT to influence transcription indirectly. | ||||||
Cardamonin | 19309-14-9 | sc-293984 sc-293984A | 10 mg 50 mg | $224.00 $940.00 | ||
Cardamonin inhibits the NF-kB pathway by blocking the phosphorylation of IκBα and its subsequent degradation. This enhances the nuclear presence of NF-kB, where UXT may interact with it to modulate the transcription of target genes. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 selectively inhibits IKK-β, stabilizing IκB and leading to increased nuclear NF-kB. UXT's interaction with NF-kB could be influenced by TPCA-1's effect on the pathway, potentially enhancing the transcriptional activity of NF-kB. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
PDTC inhibits the degradation of IκB, resulting in increased nuclear translocation of NF-kB. UXT may enhance the activity of NF-kB that is modulated by PDTC. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
Anacardic acid inhibits NF-kB activation by preventing the phosphorylation of IκBα. This action results in increased nuclear NF-kB activity, with which UXT could interact to modulate transcriptional regulation. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol inhibits NF-kB activation by blocking the translocation of the p65 subunit to the nucleus. UXT could modulate the elevated levels of NF-kB in the cytoplasm, indirectly affecting transcriptional activity. | ||||||